<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Pediatr Genet</journal-id>
<journal-id journal-id-type="iso-abbrev">J Pediatr Genet</journal-id>
<journal-id journal-id-type="doi">10.1055/s-00029027</journal-id>
<journal-title-group>
<journal-title>Journal of Pediatric Genetics</journal-title>
</journal-title-group>
<issn pub-type="ppub">2146-4596</issn>
<issn pub-type="epub">2146-460X</issn>
<publisher>
<publisher-name>Georg Thieme Verlag KG</publisher-name>
<publisher-loc>Stuttgart · New York</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27617125</article-id>
<article-id pub-id-type="pmc">4918718</article-id>
<article-id pub-id-type="doi">10.1055/s-0035-1564441</article-id>
<article-id pub-id-type="publisher-id">1504</article-id>
<article-categories>
<subj-group>
<subject>Review Article</subject>
</subj-group>
<series-title>Genetic Advances in Intellectual Disability</series-title>
<series-text>Guest Editor: Donatella Milani, MD</series-text>
</article-categories>
<title-group>
<article-title>Neurocutaneous Manifestations of Genetic Mosaicism</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>van Steensel</surname>
<given-names>Maurice A. M.</given-names>
</name>
<xref ref-type="aff" rid="AF1504-1">1</xref>
<xref ref-type="aff" rid="AF1504-2">2</xref>
<xref ref-type="author-notes" rid="CO1504-1"></xref>
</contrib>
</contrib-group>
<aff id="AF1504-1">
<label>1</label>
<institution>Division of Cancer Science, School of Medicine, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, United Kingdom</institution>
</aff>
<aff id="AF1504-2">
<label>2</label>
<institution>Institute of Medical Biology, A*STAR, Singapore</institution>
</aff>
<author-notes>
<corresp id="CO1504-1"><bold>Address for correspondence </bold>Maurice A. M. van Steensel, MD, PhD <institution>Division of Cancer Science, School of Medicine</institution><institution>Division of Biological Chemistry and Drug Discovery</institution><institution>School of Life Sciences, University of Dundee</institution><addr-line>James Arrott Drive 1, Dundee DD1 9SY</addr-line><country>United Kingdom</country><email>m.vansteensel@dundee.ac.uk</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>30</day>
<month>11</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="ppub">
<month>9</month>
<year>2015</year>
</pub-date>
<volume>4</volume>
<issue>3</issue>
<fpage>144</fpage>
<lpage>153</lpage>
<history>
<date date-type="received">
<day>24</day>
<month>5</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>25</day>
<month>5</month>
<year>2015</year>
</date>
</history>
<permissions>
<copyright-statement>© Thieme Medical Publishers</copyright-statement>
</permissions>
<abstract>
<p>Genetic mosaicism is defined as the presence of two or more genetically distinct cell populations in a single individual. Ever more disorders are found to be manifestations of mosaicism and together constitute a significant proportion of the morbidity confronting pediatric specialists. An emerging category is that of overgrowth syndromes with skin manifestations and neurological or developmental abnormalities, such as the well-known Proteus syndrome. In recent years, we have seen dramatic advances in our understanding of these disorders and we now know the genetic basis of many of them. This has profound consequences for diagnosis, counselling, and even treatment, with therapies targeted to specific pathways becoming available for clinical use. Recognizing such overgrowth syndromes, therefore, is more important than ever. Fortunately, their skin manifestations can provide important diagnostic clues when evaluated in the entire phenotypic context. In this review, I provide an overview of the most frequently seen mosaic neurocutaneous phenotypes and discuss their molecular basis.</p>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>mosaicism</kwd>
<kwd>skin</kwd>
<kwd>brain</kwd>
<kwd>overgrowth</kwd>
<kwd>intellectual disability</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>